Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 14.97% and Operating profit at 10.10% over the last 5 years
2
With a growth in Net Sales of 12.52%, the company declared Very Positive results in Mar 26
3
With ROE of 8.78%, it has a attractive valuation with a 1.52 Price to Book Value
4
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.15%
0%
-10.15%
6 Months
-9.88%
0%
-9.88%
1 Year
4.42%
0%
4.42%
2 Years
72.94%
0%
72.94%
3 Years
-16.45%
0%
-16.45%
4 Years
-17.86%
0%
-17.86%
5 Years
-32.15%
0%
-32.15%
Zhejiang Dayang Biotech Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.97%
EBIT Growth (5y)
10.10%
EBIT to Interest (avg)
10.37
Debt to EBITDA (avg)
0.12
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.64
Tax Ratio
10.04%
Dividend Payout Ratio
48.95%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.61%
ROE (avg)
7.03%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
1.52
EV to EBIT
21.76
EV to EBITDA
15.20
EV to Capital Employed
1.50
EV to Sales
1.71
PEG Ratio
0.48
Dividend Yield
1.13%
ROCE (Latest)
6.90%
ROE (Latest)
8.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
278.10
247.20
12.50%
Operating Profit (PBDIT) excl Other Income
28.00
40.60
-31.03%
Interest
0.80
1.00
-20.00%
Exceptional Items
0.00
-0.40
100.00%
Consolidate Net Profit
30.90
29.30
5.46%
Operating Profit Margin (Excl OI)
100.70%
98.20%
0.25%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 12.50% vs 27.75% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 5.46% vs 73.37% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,040.90
906.70
14.80%
Operating Profit (PBDIT) excl Other Income
173.50
132.70
30.75%
Interest
4.90
7.30
-32.88%
Exceptional Items
-17.40
-6.50
-167.69%
Consolidate Net Profit
100.10
63.70
57.14%
Operating Profit Margin (Excl OI)
96.80%
70.60%
2.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.80% vs -1.05% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 57.14% vs 27.40% in Dec 2024
About Zhejiang Dayang Biotech Group Co., Ltd. 
Zhejiang Dayang Biotech Group Co., Ltd.
Chemicals & Petrochemicals
No Details Available.
Company Coordinates 
No Company Details Available






